Encenicline
(Redirected from EVP-6124)
Encenicline[edit | edit source]
Encenicline is a pharmaceutical compound that acts as a selective partial agonist of the _7 nicotinic acetylcholine receptor. It has been investigated for its potential use in the treatment of cognitive impairment associated with schizophrenia and Alzheimer's disease.
Mechanism of Action[edit | edit source]
Encenicline binds to the _7 nicotinic acetylcholine receptor, which is a subtype of the nicotinic acetylcholine receptor family. These receptors are ion channels that, when activated, allow the flow of ions such as calcium and sodium into the cell. The activation of these receptors is thought to enhance neurotransmission and improve cognitive function by modulating the release of neurotransmitters such as dopamine, glutamate, and acetylcholine.
Clinical Development[edit | edit source]
Encenicline has undergone several clinical trials to evaluate its efficacy and safety in treating cognitive deficits. Initial studies showed promise in improving cognitive performance in patients with schizophrenia and Alzheimer's disease. However, further trials were necessary to confirm these findings and to better understand the drug's safety profile.
Potential Benefits[edit | edit source]
The potential benefits of encenicline include improved cognitive function, particularly in areas such as memory, attention, and executive function. These improvements could significantly enhance the quality of life for individuals suffering from cognitive impairments due to neurodegenerative diseases or psychiatric disorders.
Side Effects[edit | edit source]
Like many pharmaceuticals, encenicline may cause side effects. Commonly reported side effects include gastrointestinal disturbances, such as nausea and vomiting, as well as headache and dizziness. The safety and tolerability of encenicline continue to be evaluated in ongoing studies.
Research and Development[edit | edit source]
Research into encenicline is part of a broader effort to develop new treatments for cognitive impairments. The focus on the _7 nicotinic acetylcholine receptor is due to its role in cognitive processes and its potential as a therapeutic target. Ongoing research aims to optimize the efficacy and safety of encenicline and similar compounds.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
